PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-36.98%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-26.05%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-129.84%
Negative EBIT growth while 5715.T is at 31.96%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-151.38%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-173.20%
Negative net income growth while 5715.T stands at 41.84%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-173.27%
Negative EPS growth while 5715.T is at 41.85%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-173.27%
Negative diluted EPS growth while 5715.T is at 41.85%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.63%
Negative OCF growth while 5715.T is at 2.89%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-13.63%
Negative FCF growth while 5715.T is at 2.89%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
112.34%
10Y revenue/share CAGR above 1.5x 5715.T's 39.06%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
41.54%
5Y revenue/share CAGR above 1.5x 5715.T's 13.41%. David Dodd would look for consistent product or market expansions fueling outperformance.
10.69%
3Y revenue/share CAGR under 50% of 5715.T's 38.58%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.41%
Negative 10Y net income/share CAGR while 5715.T is at 288.09%. Joel Greenblatt sees a major red flag in long-term profit erosion.
48.41%
5Y net income/share CAGR 1.25-1.5x 5715.T's 35.37%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
-9.44%
Negative 3Y CAGR while 5715.T is 202.09%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
119.65%
10Y equity/share CAGR in line with 5715.T's 118.02%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
36.70%
5Y equity/share CAGR is in line with 5715.T's 35.84%. Walter Schloss would see parallel mid-term profitability and retention policies.
25.80%
3Y equity/share CAGR at 50-75% of 5715.T's 34.97%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.79%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
13.43%
Inventory growth well above 5715.T's 15.21%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-7.95%
Negative asset growth while 5715.T invests at 3.97%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
3.07%
Similar to 5715.T's 2.95%. Walter Schloss finds parallel capital usage or profit distribution strategies.
-4.40%
We’re deleveraging while 5715.T stands at 7.96%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-18.67%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
19.64%
SG&A growth well above 5715.T's 12.44%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.